Prostate cancer as a first and second cancer: effect of family history.
BACKGROUND
Diagnosis with prostate cancer has been reported to increase the risk of subsequent tumours. However, specific data on individuals with a parental history are not available so far.


METHODS
On the basis of the nationwide Swedish Family-Cancer Database including 18,207 primary invasive prostate cancers, standardised incidence ratios (SIRs) were used to estimate the relative risks of subsequent tumours after prostate cancer in the general population and among individuals with a parental history of cancer.


RESULTS
A significantly increased SIR of colorectal cancer was found among prostate cancer patients with a parental history of colorectal cancer (2.26, 11 cases). The SIRs of parental concordant (same site) tumours after prostate cancer were also increased for urinary bladder cancer (4.42, 4 cases) and chronic lymphoid leukaemia (38.0, 2 cases).


CONCLUSIONS
A higher than additive and multiplicative interaction was observed between the individual history of prostate cancer and parental history of colorectal and urinary bladder cancers, although the number of cases did not permit the rejection of any interaction model. The results suggest that the occurrence of second tumours, for example bladder after prostate or prostate after bladder tumours, is mostly related to shared genetic and non-genetic risk factors rather than treatment of first cancer.
Zhang
H
H
Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany.
Bermejo
J L
JL
Sundquist
J
J
Hemminki
K
K
D005190:Family; D006801:Humans; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000209:etiology / Q000235:genetics
Acta Oncol. 2001;40(6):772-7
11765074
Nat Genet. 2008 Mar;40(3):310-5
18264096
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):661-8
16545920
Prog Urol. 2007 Feb;17(1):35-40
17373234
IARC Sci Publ. 2004;(157):289-97
15055302
J Urol. 2008 Jan;179(1):91-5; discussion 95
17997457
J Urol. 1997 Jan;157(1):65-7
8976217
Eur J Cancer. 2007 Jul;43(11):1694-700
17531466
Cancer. 1997 Apr 15;79(8):1600-4
9118045
J Cell Biochem. 2006 Feb 15;97(3):433-47
16267836
J Urol. 2006 Feb;175(2):788-9; author reply 789
16407052
Int J Cancer. 2001 Jul 15;93(2):155-61
11410860
Thyroid. 2007 Dec;17(12):1277-88
18020916
Br J Cancer. 2005 Oct 3;93(7):838-41
16136048
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):669-73
16887293
Gastroenterology. 2005 Apr;128(4):819-24
15825064
Arch Ophthalmol. 2005 May;123(5):601-4
15883277
J Urol. 2008 May;179(5 Suppl):S2-5
18405742
Leuk Res. 2005 Jan;29(1):59-61
15541476
N Engl J Med. 2008 Feb 28;358(9):910-9
18199855
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):315-6
10974441
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2020-6
17057028
Eur Urol. 2007 Oct;52(4):973-82
17644245
Nat Genet. 2008 Mar;40(3):281-3
18264098
J Natl Cancer Inst. 2005 Nov 2;97(21):1575-9
16264177
Cancer. 2006 Sep 1;107(5):991-8
16878323
J Natl Cancer Inst. 2006 Jan 4;98(1):15-25
16391368
Nat Genet. 2008 Mar;40(3):316-21
18264097
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):637-9
16751057
Urol Int. 2005;75(3):213-6
16215307
Hered Cancer Clin Pract. 2006 Dec 15;4(4):186-92
20223022